The site coordinator opens the IRT portal on a Tuesday morning and sees what no one wants to see three weeks into active enrollment: the depot shipment is flagged as delayed, the site’s on-hand inventory covers four patients, and there are six scheduled dosing visits before the end of the month. The vendor passed every qualification check. The IND is clean. The audit certificate is current. None of that gets drug to the site by Friday.
This is the gap that certification cannot close. Regulatory qualification tells you a vendor met a standard at a point in time. It says nothing about whether that vendor will perform against your trial’s specific fulfillment pattern, your site’s visit density, or the inventory buffer your IRT is actually configured to trigger. Those are operational questions, and right now most programs answer them with a patchwork of CTMS exports, IRT reports, and manual spreadsheets that nobody reconciles until a site calls the CTM in a panic.
The Compliance Ceiling
The FDA’s Guidance for Industry: CGMP for Phase 1 Investigational Drugs sets the manufacturing and documentation floor for investigational product vendors. It defines what a qualified facility looks like. What it cannot define is whether that facility’s distribution cadence matches your enrollment acceleration in month four of a Phase II. Those are different things, and conflating them is exactly how supply disruptions happen on otherwise compliant programs.
The operational truth is that most sponsor clinical operations teams have two separate conversations with two separate teams about the same vendor. Quality talks to the vendor about certificates of analysis, deviation logs, and audit findings. Supply chain talks to the same vendor about depot allocations, expiry management, and shipment SLAs. Sites talk to neither. By the time a fulfillment problem surfaces at the site level, it has already been visible in the data for weeks, sitting in a column no one was watching.
IMP waste from poor forecasting and planning can reach as high as 50% of a trial’s supply, according to analysis of clinical trial supply management programs. That figure is not an indictment of vendors. It reflects what happens when supply models are built on enrollment assumptions that stopped being accurate the moment the first site deviated from projections. A vendor can be fully compliant and still be shipping to a forecast that is two months out of date.
One trial supply program that shifted from static to dynamic IRT configuration, adjusting supply parameters against actual enrollment and site data rather than fixed baseline assumptions, saved approximately $6 million, roughly 25% of that trial’s total supply budget. The vendor did not change. The qualification status did not change. What changed was the operational layer sitting between the vendor’s performance and the site’s inventory reality.
Where the Tracking Actually Breaks
Ask any CTM where the site’s current on-hand inventory count lives and you will get one of three answers: the IRT portal, the CTMS, or a spreadsheet the site coordinator maintains manually. Rarely are these three numbers the same. The IRT reflects what was dispensed against what was shipped. The CTMS reflects what was entered at monitoring visits. The spreadsheet reflects what the coordinator actually counted last Thursday. Sites manage against the spreadsheet because it is the only number they trust.
This fragmentation has direct enrollment consequences. When a site’s IRT reorder threshold is set too conservatively, drug sits in the depot instead of the pharmacy. When it is set too aggressively, the site runs short during a visit density spike. Across the sites I work with at CliniBiz, a frequent finding during pre-enrollment readiness checks is an IRT configuration that was set at startup and never reconciled against the site’s actual patient flow. The startup team built the model. Nobody updated it after the first amendment changed the visit schedule.
Protocol amendments sharpen this problem considerably. Published data on amendment cost impacts put the median direct implementation cost at $141,000 for a Phase II protocol and $535,000 for a Phase III protocol. Those figures capture regulatory resubmission, site retraining, and IRB fees. Those figures may not capture all supply chain rework that can follow a schedule change: revised depot allocations, updated expiry calculations, IRT parameter updates, and the gap period between amendment approval and resupply arrival at the site. That gap is where enrollment pauses. That pause is where screen failures accumulate.
ICH E6(R3) places direct responsibility on the sponsor for ensuring investigational product is delivered to sites in a timely manner and that records of product delivery, inventory, and disposition are maintained. The requirement exists. The operational infrastructure to meet it in real time, across a 40-site Phase III with four depots and a mid-study amendment, frequently does not.
What Changes on Monday
For sponsor clinical operations leads, the fix starts before the first SIV. IRT configuration reviews need to include site-specific visit density projections, not just overall enrollment assumptions. That means the site feasibility data that drove site selection should be feeding the IRT setup, and both should be revisited at every protocol amendment, not just at the annual supply review. Any contract amendment that changes the visit schedule or patient population should automatically trigger an IRT parameter reconciliation. Build that into the amendment workflow as a mandatory checklist item, not an afterthought.
For sites, the ask is simpler but equally important: stop treating on-hand inventory counts as a monitoring visit task. A monthly reconciliation between what the IRT shows as dispensed, what the pharmacy log shows as received, and what is physically on the shelf catches discrepancies before they become shortages. Sites that surface those discrepancies proactively, through the CTM rather than waiting for the next monitoring visit, give sponsors a remediation window. Sites that surface them when a patient arrives for a dosing visit do not.
The vendor’s audit certificate tells the FDA that the facility operates to standard. It tells the site coordinator nothing about whether drug will arrive before the Thursday visit. Those are two separate guarantees, and only one of them is built into most trial programs by design. The other has to be built in deliberately, or the site finds out the hard way which one was missing.
References
- Clinical Trials Arena, “Supply continuity in clinical trials: Why certification alone is not enough”
- FDA, “Guidance for Industry: CGMP for Phase 1 Investigational Drugs”
- PubMed, “Cost and impact of protocol amendments in clinical trials”
- Medpath, “Clinical Trial Supply Forecasting: Why Data Currency, Not Algorithms, Drives Waste Reduction”
